Singh Mukesh, Chin Shui Hao, Giles Paul D, Crothers David, Al-Allaf Karim, Khan Jawad M
Department of Internal Medicine, Chicago Medical School, North Chicago, Ilinois 60064, USA.
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):556-61. doi: 10.1097/HJR.0b013e328338978e.
The prevalence of high-density lipoprotein cholesterol (HDL-C) in patients who have achieved low-density lipoprotein cholesterol (LDL-C) targets in the current era of universal statin therapy remains unknown. We conducted a study to determine the prevalence of low HDL-C in patients with documented coronary artery disease, and to determine the lipid-lowering treatment patterns in secondary prevention of coronary artery disease.
In this retrospective cohort analysis, data were obtained from the electronic database of a cardiology clinic. The Joint British Society 2 criteria were used defining low HDL-C as less than 1 mmol/l in males and less than 1.2 mmol/l in females. We compared the prevalence of low HDL-C across the following categories of LDL-C: less than 2, 2-2.5, and greater than 2.5 mmol/l.
Two thousand and eighty-seven patients with a mean age of 64.34±11.94 years constituted the study sample. About 36.6% of patients in this study were found to have low HDL-C. Irrespective of sex, low HDL-C was prevalent across all levels of LDL-C, but interestingly this was most prevalent in patients with a LDL-C less than 2 mmol/l (43.06%). HDL-C level of 1.16±0.97 mmol/l in patients with LDL-C less than 2 mmol/l was significantly lower than 1.22±0.33 mmol/l in patients with LDL-C greater than 2 mmol/l, P value less than 0.01. There was a poor correlation between levels of HDL-C and LDL-C in the study population irrespective of sex or statin therapy.
This study shows widely prevalent low HDL-C levels in high-risk patients across the spectrum of LDL-C levels despite statin therapy. There was no correlation between the LDL-C and HDL-C levels implying their independent relationship and, thus, the need to treat them independently.
在当前普遍使用他汀类药物治疗的时代,已实现低密度脂蛋白胆固醇(LDL-C)目标的患者中高密度脂蛋白胆固醇(HDL-C)的患病率尚不清楚。我们进行了一项研究,以确定有冠状动脉疾病记录的患者中低HDL-C的患病率,并确定冠状动脉疾病二级预防中的降脂治疗模式。
在这项回顾性队列分析中,数据来自一家心脏病诊所的电子数据库。采用英国联合学会2标准,将男性HDL-C低于1 mmol/l、女性低于1.2 mmol/l定义为低HDL-C。我们比较了以下LDL-C类别中低HDL-C的患病率:低于2、2至2.5以及高于2.5 mmol/l。
2087例平均年龄为64.34±11.94岁的患者构成了研究样本。本研究中约36.6%的患者被发现HDL-C较低。无论性别如何,低HDL-C在所有LDL-C水平中均普遍存在,但有趣的是,这在LDL-C低于2 mmol/l的患者中最为普遍(43.06%)。LDL-C低于2 mmol/l的患者的HDL-C水平为1.16±0.97 mmol/l,显著低于LDL-C高于2 mmol/l的患者的1.22±0.33 mmol/l,P值小于0.01。无论性别或他汀类药物治疗如何,研究人群中HDL-C水平与LDL-C水平之间的相关性都很差。
本研究表明,尽管进行了他汀类药物治疗,但在LDL-C水平范围内的高危患者中,HDL-C水平普遍较低。LDL-C和HDL-C水平之间没有相关性,这意味着它们是独立的关系,因此需要分别进行治疗。